Cheat Sheet

TEG and ROTEM: Reading Viscoelastic Tests

What the tracing shows that PT/INR and aPTT miss, each value and the product it points to, example ranges, and TXA timing

Reviewed by Alex G, BSN, RN, CEN, CCRN, CMC, NREMT-P · Checked against current sources November 2026

Page 1 of the TEG and ROTEM: Reading Viscoelastic Tests PDF, a printed page in columns with sections on What you will do, What TEG and ROTEM add to PT/INR and aPTT, Each value and what it points to, TXA in trauma is time-based, Call for help when and Check your unit's policyEnlarge

One-page PDFLetter landscape, ready to print or keep with your notes

View PDFDownload

TEG and ROTEM: Reading Viscoelastic Tests: one-page PDF preview

Page 1 of the TEG and ROTEM: Reading Viscoelastic Tests PDF, a printed page in columns with sections on What you will do, What TEG and ROTEM add to PT/INR and aPTT, Each value and what it points to, TXA in trauma is time-based, Call for help when and Check your unit's policy

View PDFDownload

What you will do

What TEG and ROTEM add to PT/INR and aPTT

PT/INR and aPTT time only the first strands of fibrin in plasma. TEG (thromboelastography) and ROTEM (thromboelastometry) watch a whole-blood clot form, firm up and break down, so they also show fibrinogen function, platelet contribution to strength and fibrinolysis. A first result is often ready in 10–20 minutes, faster than a lab panel.

The tracing is a line that splits into a widening spindle. Time before it splits = how fast clotting starts. How steeply it opens = how fast fibrin builds. Widest point = clot strength. Narrowing after the peak = clot breaking down.

Each value and what it points to

Clot phaseTEGROTEMMainly reflectsIf abnormal, think of
StartR timeCT (clotting time)Clotting factors; heparinLong: plasma or PCC (heparin: check heparinase or HEPTEM)
Build-up speedK time, α angleCFT, α angleFibrinogen, some plateletsLong K or low angle: cryo or fibrinogen concentrate
Fibrin aloneFunctional fibrinogen MAFIBTEM A10 or MCFFibrinogen (platelets blocked)Low: cryo or fibrinogen concentrate
StrengthMAMCF, A10 (EXTEM)Platelets, then fibrinogenLow with normal fibrin part: platelets
BreakdownLY30ML; LI30 or LI60FibrinolysisHigh lysis: antifibrinolytic (TXA)
Examples only. Ranges change with the analyzer, cartridge and activator: use the ranges printed on your lab report.
ValueExample: kaolin TEG 5000Example: ROTEM sigma EXTEM CFIBTEM C
R / CT5–10 min51–73 s—
K; α angleK 1–3 min; α 53–72°Not in cleared claims—
MA / MCF50–70 mm57–72 mm (A10 45–62)MCF 6–19 mm (A10 6–17)
LysisLY30 0–8%ML 0–6% at 60 min—

TXA in trauma is time-based

Call for help when

Check your unit's policy

Check your unit's policy for which analyzer and cartridge you use, its reference ranges and treatment algorithm, who draws and runs the sample, how much discard to waste from a line, and whether TEG or ROTEM is part of your massive transfusion protocol.

In depth

The one-page summary above is what the PDF prints. These sections go further.

How the test works: analyzers and assays

Both systems put a small whole-blood sample at 37 °C, add calcium and an activator, and measure how stiff the clot becomes over time. Amplitude is in millimeters; time runs left to right. TEG 5000 uses a cup and pin; TEG 6s and ROTEM sigma use closed cartridges that run several assays at once.

SystemAssayWhat it does
TEGKaolin (CK)Contact activation; R, K, angle, MA, LY30
TEGRapidTEG (CRT)Tissue factor plus kaolin; fast MA (and TEG-ACT on TEG 5000)
TEGFunctional fibrinogen (CFF)Platelets blocked; MA shows fibrin strength
TEGKaolin with heparinase (CKH)Heparin removed; compare R with plain kaolin
ROTEMEXTEMTissue factor (extrinsic) activation
ROTEMINTEMContact (intrinsic) activation; sensitive to heparin
ROTEMFIBTEMEXTEM with platelets blocked: fibrin part only
ROTEMHEPTEMINTEM with heparinase: shows heparin effect
ROTEMAPTEM (delta)EXTEM with an antifibrinolytic: confirms lysis

Definitions: R and CT run from the start to a 2 mm amplitude. K and CFT run from 2 to 20 mm. The α angle is the slope of the opening curve. MA and MCF are the widest amplitude; A5, A10 and A20 are the amplitude 5, 10 and 20 minutes after CT, so A10 gives an early read of final strength. LY30 is the percent loss of clot 30 minutes after MA; ROTEM LI30 or LI60 is the percent of clot still left (a low number means lysis), and ML is the maximum percent lost.

The FDA-cleared TEG 6s trauma cartridge reports only CK R and LY30, CRT MA and CFF MA, with no K or angle. On that device, read fibrinogen from the functional fibrinogen MA. The US ROTEM sigma cartridge reports CT, A5 to A20, MCF, LI60 and ML.

Reading common patterns

No drawn tracing yet: picture a thin line that opens into a spindle. These are the shapes to recognize.

ShapeValuesLikely causeUsual response
Long straight line before it opens, then normal widthLong R or CTFactor deficiency, dilution, warfarin; heparin if heparinase/HEPTEM corrects itPlasma or PCC; protamine if heparin
Opens slowly, stays narrowLong K, low angle, low FIBTEM or functional fibrinogenLow fibrinogen (dilution, consumption, obstetric bleeding)Cryo or fibrinogen concentrate
Opens on time but stays narrowLow MA or MCF, normal FIBTEMLow platelet count or functionPlatelets
Opens, then pinches closed earlyHigh LY30 or ML, low LI30/LI60Hyperfibrinolysis (trauma, liver surgery)Antifibrinolytic
Opens fast and very wideShort R, high MAHypercoagulable stateDiscuss VTE prophylaxis; no products

Example treatment triggers from published algorithms

Programs set their own cutoffs. These are the ACS TQIP 2014 massive transfusion examples, given here to show the logic; your hospital may use different numbers (the Blood Products page lists a Denver rapid-TEG set and a European ROTEM set).

FindingStandard TEGRapid TEGROTEMProduct
Slow startR >9 minACT >128 sEXTEM CT >100 s or INTEM CT >230 sPlasma
Slow build-upK >4 min; α <60°K >2.5 min; α <60°FIBTEM MCF <8 mmCryo or fibrinogen concentrate and/or plasma
Weak clotMA <55 mmMA <55 mmEXTEM MCF <45 mm with FIBTEM MCF >10 mmPlatelets
LysisLY30 >7.5%LY30 >3%EXTEM ML >15%Antifibrinolytic

The European trauma guideline (6th ed., 2023) recommends a goal-directed strategy using standard labs and/or viscoelastic tests, fibrinogen concentrate or cryo (starting 3–4 g) for a viscoelastic fibrin deficit or Clauss fibrinogen 150 mg/dL (1.5 g/L) or less, avoiding plasma to correct low fibrinogen when cryo or concentrate is available, and PCC when initiation stays slow with normal fibrinogen. Ionized calcium, temperature and pH still need correcting; the test cannot show them.

Sample handling and what the test misses

Where it is used and the evidence

The Cochrane review updated in May 2026 (35 randomized trials, 3,096 patients, mostly elective cardiac surgery) found that TEG- or ROTEM-guided algorithms may lower mortality (RR 0.76) and plasma and platelet use, but the certainty of the evidence is very low.

Tranexamic acid timing in trauma

CRASH-2 (Lancet 2010) randomized 20,211 bleeding trauma patients within 8 hours of injury to TXA (1 g over 10 minutes, then 1 g over 8 hours) or placebo. All-cause death fell from 16.0% to 14.5% and bleeding death from 5.7% to 4.9%. The timing analysis (2011) found the benefit largest within 1 hour, still present at 1–3 hours, and harm after 3 hours (bleeding death 4.4% vs 3.1%).

The European guideline (2023) recommends TXA as soon as possible within 3 hours (Grade 1A) and recommends not waiting for viscoelastic results (Grade 1B). A later high LY30 can prompt more antifibrinolytic if the team decides, but the first dose is driven by the clock. Hand over the injury time, dose time and whether the 8-hour infusion is running so no one gives a duplicate bolus.

Nursing care during a viscoelastic-guided resuscitation

Practice in your browser4,850+ exam-style questions with rationales. No ads. Pro is coming in January 2027. Also on the App Store and Google Play.

Related cheat sheets

Sources

  1. American College of Surgeons Trauma Quality Improvement Program. ACS TQIP Massive Transfusion in Trauma Guidelines. October 2014. Link
  2. Rossaint R, Afshari A, Bouillon B, et al. The European guideline on management of major bleeding and coagulopathy following trauma: sixth edition. Crit Care. 2023;27(1):80. Link
  3. Gonzalez E, Moore EE, Moore HB, et al. Goal-directed hemostatic resuscitation of trauma-induced coagulopathy: a pragmatic randomized clinical trial comparing a viscoelastic assay to conventional coagulation assays. Ann Surg. 2016;263(6):1051-1059. Link
  4. Baksaas-Aasen K, Gall LS, Stensballe J, et al. Viscoelastic haemostatic assay augmented protocols for major trauma haemorrhage (ITACTIC): a randomized, controlled trial. Intensive Care Med. 2021;47(1):49-59. Link
  5. CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010;376(9734):23-32. Link
  6. CRASH-2 collaborators. The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011;377(9771):1096-1101. Link
  7. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN). Lancet. 2017;389(10084):2105-2116. Link
  8. Kvisselgaard AD, Wolthers SA, Wikkelsø AJ, et al. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev. 2026;5:CD007871. Link
  9. US Food and Drug Administration. 510(k) decision summary K201440: ROTEM sigma Thromboelastometry System (Tem Innovations / Werfen), reference intervals. 2022. Link
  10. US Food and Drug Administration. 510(k) decision summary K183160: TEG 6s Hemostasis System, Citrated: K, RT, FF Assay Cartridge (Haemonetics). Link